RedHill's oral pill shows promise against Covid-related pneumonia
Zee News
The oral opaganib is associated with a reduction in the need for supplemental oxygen support, earlier time to discharge from hospital and was well tolerated, the company said in a statement on Monday.
Tel Aviv: Israel-based biopharmaceutical company RedHill Biopharma's new oral pill called Opaganib has been found effective in patients hospitalised with COVID-related pneumonia, results from a clinical trial has shown. The oral opaganib is associated with a reduction in the need for supplemental oxygen support, earlier time to discharge from hospital and was well tolerated, the company said in a statement on Monday. The Phase II trial analysed data from the 40-patient who were randomised to receive either opaganib or placebo in addition to standard of care (SoC), predominantly including dexamethasone and/or remdesivir.More Related News